Wells Fargo
ACAD icon

Wells Fargo’s Acadia Pharmaceuticals ACAD Stock Holding History

Wells Fargo’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$1.29M – 6841
2021
Q1 		$1.29M Buy
+50,000
New +$2.2M ﹤0.01% 4067

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wells Fargo's ACAD Position: Q1 2026 in Review

Wells Fargo reduced its Acadia Pharmaceuticals (ACAD) stake by 43% in Q1 2026, selling an estimated $2.17M and leaving 118,525 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

Wells Fargo first reported a position in ACAD in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.6M in Q2 2020. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Wells Fargo held 118,525 shares of Acadia Pharmaceuticals worth $2.64M as of Q1 2026.
  • Wells Fargo sold 90,663 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.17M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3059 holding.
  • Wells Fargo first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Acadia Pharmaceuticals position peaked at $10.6M in Q2 2020.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.